Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-α in patients with HIV-lipodystrophy

HIV Medicine

Volumn 7, Issue 3, 2006, Pages 163-172

  Haugaard, Steen B ^a   Andersen, O ^a   Pedersen, S B ^b   Dela, F ^c   Deacon, C F ^c   Holst, J J ^c   Iversen, J ^a   Madsbad, S ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cell; HIV; IVGTT; Lipodystrophy; Prehepatic insulin secretion

Indexed keywords

ALANINE; ANTIRETROVIRUS AGENT; C PEPTIDE; GLUCAGON; GLUCOSE; INDINAVIR; INSULIN; LACTIC ACID; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCAGON BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTATE BLOOD LEVEL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DENATURATION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALANINE; C-PEPTIDE; CASE-CONTROL STUDIES; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LACTATES; MALE; MIDDLE AGED; STIMULATION, CHEMICAL; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644761924     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00364.x     Document Type: Article

References (52)

1. Chen D, Misra A, Garg A. Clinical Review 153 Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845-4856.
2. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-735.
3. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: Pathogenesis, prognosis, treatment, and controversies. Annu Rev Med 2004; 55: 303-317.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-2099.
5. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.
6. Kosmiski LA, Kuritzkes DR, Lichtenstein KA et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15: 1993-2000.
7. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312-321.
8. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl. 3): 35-45.
9. Kahn SE, Prigeon RL, McCulloch DK et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672.
10. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004; 135: 273-279.
11. Vigouroux C, Maachi M, Nguyen TH et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17: 1503-1511.
12. Gunawardana SC, Sharp GW. Intracellular pH plays a critical role in glucose-induced time-dependent potentiation of insulin release in rat islets. Diabetes 2002; 51: 105-113.
13. Brennan L, Shine A, Hewage C et al. A nuclear magnetic resonance-based demonstration of substantial oxidative 1-alanine metabolism and 1-alanine-enhanced glucose metabolism in a clonal pancreatic beta-cell line: Metabolism of 1-alanine is important to the regulation of insulin secretion. Diabetes 2002; 51: 1714-1721.
14. Kwon G, Xu G, Marshall CA, McDaniel ML. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999; 274: 18702-18708.
15. Moens K, Berger V, Ahn JM et al. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 2002; 51: 669-675.
16. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
17. Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000; 43: 1012-1019.
18. Tripathy D, Carlsson M, Almgren P et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: Lessons from the Botnia Study. Diabetes 2000; 49: 975-980.
19. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
20. Christiansen E, Tibell A, Volund A et al. Insulin secretion, insulin action and non-insulin-dependent glucose uptake in pancreas transplant recipients. J Clin Endocrinol Metab 1994; 79: 1561-1569.
21. Haugaard SB, Andersen O, Storgaard H et al. Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of {beta}-cells. Am J Physiol Endocrinol Metab 2004; 287: E677-E685.
22. Andersen O, Haugaard SB, Andersen UB et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003; 52: 1343-1353.
23. Fogh-Andersen N, D'Orazio P. Proposal for standardizing direct-reading biosensors for blood glucose. Clin Chem 1998; 44: 655-659.
24. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 1983; 24: 359-365.
25. Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H. Effects of insulin on glucose turnover rates in vivo: Isotope dilution versus constant specific activity technique. Metabolism 1996; 45: 82-91.
26. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA. Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 2002; 51: 1271-1280.
27. Cunningham VJ, Heath DF. An interpretation of the intravenous glucose tolerance test in the light of recent findings on the kinetics of glucose and insulin in man. Clin Sci Mol Med 1978; 54: 161-173.
28. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3853-3860.
29. Hovorka R, Soons PA, Young MA. ISEC: A program to calculate insulin secretion. Comput Meth Programs Biomed 1996; 50: 253-264.
30. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA. Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: Accuracy and required sampling schedule. Diabetologia 1998; 41: 548-554.
31. Kjems LL, Volund A, Madsbad S. Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: Assessment of insulin secretion by mathematical methods. Diabetologia 2001; 44: 1339-1348.
32. Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390.
33. Gastaldelli A, Baldi S, Pettiti M et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: A quantitative study. Diabetes 2000; 49: 1367-1373.
34. Kjems LL, Kirby BM, Welsh EM et al. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 2001; 50: 2001-2012.
35. Storgaard H, Jensen CB, Vaag AA, Volund A, Madsbad S. Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism 2003; 52: 885-894.
36. Pighin D, Karabatas L, Rossi A, Chicco A, Basabe JC, Lombardo YB. Fish oil affects pancreatic fat storage, pyruvate dehydrogenase complex activity and insulin secretion in rats fed a sucrose-rich diet. J Nutr 2003; 133: 4095-4101.
37. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
38. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
39. Sekhar RV, Jahoor F, White AC et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283: E332-E337.
40. Sutinen J, Hakkinen AM, Westerbacka J et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16: 2183-2193.
41. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-339.
42. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999; 189: 1053-1062.
43. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
44. Iozzo P, Pratipanawatr T, Pijl H et al. Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. Am J Physiol Endocrinol Metab 2001; 280: E712-E719.
45. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286: E296-E303.
46. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002; 51: 1143-1147.
47. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000; 85: 35-41.
48. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
49. Ben Romano R, Rudich A, Tirosh A et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 2004; 47: 1107-1117.
50. Luzi L, Perseghin G, Tambussi G et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003; 284: E274-E280.
51. Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Jarvinen H, Ferrannini E. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the study of Insulin Resistance. J Clin Endocrinol Metab 1999; 84: 863-868.
52. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 442-448.